Research programme: inflammatory disorder therapeutics - MedImmune/University System of Maryland

Drug Profile

Research programme: inflammatory disorder therapeutics - MedImmune/University System of Maryland

Latest Information Update: 09 May 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator MedImmune; University System of Maryland
  • Class
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders; Inflammation; Respiration disorders

Most Recent Events

  • 29 Apr 2014 MedImmune and the University System of Maryland agree to co-develop inflammatory disorder therapeutics in USA
  • 29 Apr 2014 Early research in Autoimmune disorders in USA (unspecified route)
  • 29 Apr 2014 Early research in Inflammation in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top